(210 days)
No
The document does not mention AI, ML, or related terms, and the device description focuses on standard monitoring and defibrillation functions.
Yes
The device is described as a defibrillator/monitor and its intended use includes non-invasively measuring blood pressure and continuously monitoring carbon dioxide concentration, all of which are interventions aimed at treating or monitoring a patient's medical condition.
Yes
The device is described as a "defibrillator / monitor" with capabilities including "3 lead ECG, interpretive 12 lead ECG and pulse oximeter," which are used to measure and monitor physiological parameters indicating a diagnostic function. The sections on NIBP and EtCO2 further specify the non-invasive measurement and monitoring of blood pressure and carbon dioxide concentration, respectively, which are diagnostic indicators.
No
The device description explicitly states it is a "defibrillator / monitor series" and lists various hardware components like a defibrillator, monitor, pacemaker, ECG, and pulse oximeter.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The LIFEPAK®12, as described, measures physiological parameters directly from the patient's body (blood pressure and carbon dioxide in breath). It does not analyze samples taken from the body.
- Intended Use: The intended use clearly states non-invasive measurement and monitoring of blood pressure and carbon dioxide concentration of expired and inspired breath. This is in-vivo measurement, not in-vitro.
Therefore, the LIFEPAK®12 falls under the category of a medical device used for patient monitoring and treatment, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The only modification to the LIFEPAK®12 described in K973486 is the additional capability to non-invasively monitor blood pressure and expired / inspired carbon dioxide.
The use of the LIFEPAK®12 capnograph monitor is indicated for a patient that requires the continuous, noninvasive measurement and monitoring of carbon dioxide concentration of expired and inspired breath and respiration rate.
The use of the LIFEPAK®12 blood pressure monitor is indicated for a patient that requires the noninvasive measurement of arterial blood pressure using the oscillometric measurement technique, which provides values for the patient's systolic, diastolic, mean arterial pressure and pulse rate.
Product codes (comma separated list FDA assigned to the subject device)
74DXN, 74CCK
Device Description
The LIFEPAK®12 defibrillator / monitor series is a complete acute cardiac response system - battery or auxiliary powered defibrillator (manual and AED), monitor, pacemaker, 3 lead ECG, interpretive 12 lead ECG and pulse oximeter. Data can be transmitted by landline or cell phone to computer, fax, printer, or ECG storage system.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adult and pediatric patients
Intended User / Care Setting
The users will be Advanced Life Support and Basic Life Support providers in a variety of hospital and pre-hospital settings. Emergency Medical Services users will include Paramedics and Emergency Medical Technicians trained and authorized to respond to medical emergencies. This device will be used in the pre-hospital setting and in the hospital, in critical areas (emergency departments, critical care, operating rooms, etc.) and on general duty floors (e.g. medical/surgical). It will also be used for patient transport (air and ground ambulance, in hospital transport, etc.)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The NIBP and CO2 Options for the Physio-Control LIFEPAK®12 is subject to extensive safety and performance testing prior to release. Final testing for the system includes various performance tests designed to ensure that the device meets all of its functional requirements and performance specifications. Safety testing will be performed by third party agencies to ensure the device complies to applicable industry and safety standards. The LIFEPAK®12 is also subject to testing to assure compliance to the requirements of various standards:
ANSI/AAMI SP-10-1992, Electronic or Automated Sphygmomanometers
IEC 601-2-30; 1995 Medical Electrical Equipment - Part 2: Particular Requirements for the Safety of Automatic Cycling Indirect Blood Pressure Monitoring Equipment.
IEC 601-1, Medical Electrical Equipment - Part 1: General Requirements for Safety.
EN 864; 1997 Medical Electrical Equipment - Capnometers for use with humans - Particular requirements.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
K982135, K914838, K981114, K964239
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1130 Noninvasive blood pressure measurement system.
(a)
Identification. A noninvasive blood pressure measurement system is a device that provides a signal from which systolic, diastolic, mean, or any combination of the three pressures can be derived through the use of tranducers placed on the surface of the body.(b)
Classification. Class II (performance standards).
0
SEP 1 1999
510(k) SUMMARY
Modification 510(k) Premarket Notification Submission NIBP and CO2 Options for the Physio-Control LIFEPAK®12 Defibrillator / Monitor System
| 1. | Submitter's Name | Michael D. Willingham
Vice President, Quality and Regulatory Affairs |
|----|------------------|-----------------------------------------------------------------------------------------------|
| | Company | Physio-Control Corporation
11811 Willows Road NE
PO Box 97006
Redmond, WA 98073-9708 |
| | Telephone: | (425) 867-4329 |
| | Facsimile: | (425) 867-4154 |
NIBP and CO2 Options for the Physio-Control LIFEPAK®12 Name of Device 2. Defibrillator / Monitor System
- Noninvasive Blood Pressure Measurement System Classification: 74DXN: 21 CFR 870.1130 Class II
Analyzer, Gas, Carbon-Dioxide, Gaseous-Phase 74CCK; 21 CFR 868.1400 Class II
dioxide monitoring blood pressure and carbon 3. Noninvasive Predicate the existing Physio-Control has been added to Device(s) capabilities LIFEPAK®12 described in K973486. The intended use and function of the modified Physio-Control LIFEPAK®12 is substantially equivalent to the following devices:
The Non-invasive blood pressure (NIBP) monitor portion of this 510(k) submission is substantially equivalent to Oscillomate EMS NIBP Monitor Model 9001 (510[k] reference K982135) and the PROPAQ Models 102, 104, 106, (510[k] reference K914838). All devices non-invasively measure the blood pressure of adult and pediatric patients primarily in the emergency care environment.
The Carbon-Dioxide Gas Analyzer portion of this 510(k) submission is substantially equivalent to MICROCAP (510[k] reference K981114) and NPB-75 (510[k] reference K964239). All devices non-invasively measure the carbon dioxide concentration of the expired and inspired breath and respiration rate.
1
-
- Device The LIFEPAK®12 defibrillator / monitor series is a complete acute cardiac response system - battery or auxiliary powered Description defibrillator (manual and AED), monitor, pacemaker, 3 lead ECG, interpretive 12 lead ECG and pulse oximeter. Data can be transmitted by landline or cell phone to computer, fax, printer, or ECG storage system.
The users will be Advanced Life Support and Basic Life Support providers in a variety of hospital and pre-hospital settings. Emergency Medical Services users will include Paramedics and Emergency Medical Technicians trained and authorized to respond to medical emergencies. This device will be used in the pre-hospital setting and in the hospital, in critical areas (emergency departments, critical care, operating rooms, etc.) and on general duty floors (e.g. medical/surgical). It will also be used for patient transport (air and ground ambulance, in hospital transport, etc.)
- Device The LIFEPAK®12 defibrillator / monitor series is a complete acute cardiac response system - battery or auxiliary powered Description defibrillator (manual and AED), monitor, pacemaker, 3 lead ECG, interpretive 12 lead ECG and pulse oximeter. Data can be transmitted by landline or cell phone to computer, fax, printer, or ECG storage system.
-
Intended Use The only modification to the LIFEPAK®12 described in న. K973486 is the additional capability to non-invasively monitor blood pressure and expired / inspired carbon dioxide.
The use of the LIFEPAK®12 capnograph monitor is indicated for a patient that requires the continuous, noninvasive measurement and monitoring of carbon dioxide concentration of expired and inspired breath and respiration rate.
The use of the LIFEPAK®12 blood pressure monitor is indicated for a patient that requires the noninvasive measurement of arterial blood pressure using the oscillometric measurement technique, which provides values for the patient's systolic, diastolic, mean arterial pressure and pulse rate.
-
- Comparison of The design, components, storage technology and energy source are similar to its predicate devices. All systems provide a Technological Characteristics means for interfacing with a patient, collecting parameter specific physiologic data, and processing the data for alarm generation and display of numeric values and waveforms on the LIFEPAK®12 display screen.
2
The NIBP and CO2 Options for the Physio-Control LIFEPAK®12 is subject to extensive safety and performance testing prior to release. Final testing for the system includes various performance tests designed to ensure that the device meets all of its functional requirements and performance specifications. Safety testing will be performed by third party agencies to ensure the device complies to applicable industry and safety standards. The LIFEPAK®12 is also subject to testing to assure compliance to the requirements of various standards:
ANSI/AAMI SP-10-1992, Electronic or Automated Sphygmomanometers
IEC 601-2-30; 1995 Medical Electrical Equipment - Part 2: Particular Requirements for the Safety of Automatic Cycling Indirect Blood Pressure Monitoring Equipment.
IEC 601-1, Medical Electrical Equipment - Part 1: General Requirements for Safety.
EN 864; 1997 Medical Electrical Equipment - Capnometers for use with humans - Particular requirements.
In conclusion, the NIBP and CO2 Options for the Physio-Control LIFEPAK®12 are as safe and effective as the predicate devices and raises no new issues.
3
Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a symbol that resembles three stylized human figures.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
SEP ।
Mr. Michael D. Willingham Vice President, Quality and Regulatory Affairs Medtronic Physio-Control 11811 Willows Road NE Post Office Box 97006 Redmond, WA 98073-9706
Re: K990338 NIBP & CO2 Options for the LIFEPAK® 12 Defibrillator/Monitor System Requlatory Class: II (Two) Product Code: 74 DXN Dated: July 19, 1999 Received: July 20, 1999
Dear Mr. Willingham:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to A substantially equivalent determination assumes compliance with 895. the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have
4
Page 2 - Mr. Michael D. Willingham
under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the requlation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Thomas J. Callahan
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory and Neurological Devices Office of Device Evaluation Center for Devices and Radioloqical Health
Enclosure
5
510(k) Number (if known): _ _ _ K 990 338
Options for the LIFEPARC 12 Device Name: NIBP CO2 ibnellator/ Noniter System
Indications For Use:
NIBP
The LIFEPAK®12 NIBP monitor non-invasively measures blood pressure of the adult and pediatric patients by professionally trained health care providers. It is not designed for continuous, unsupervised monitoring.
EtCO2
The use of the LIFEPAK®12 EtCo2 monitor is indicated whenever professionally trained health care providers determine that a patient requires the continuous, non invasive measurement and monitoring of carbon dioxide concentration of the expired and inspired breath and respiration rate.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| K990338 |
|---|
| --------- |
| (Division Sign-Off) | |
|---|---|
| Division of Cardiovascular, Respiratory, | |
| and Neurological Devices | |
| 510(k) Number |
Signature
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)